The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling studyNora Schmit, Peter Winskill, Toussaint Rouamba et al.|The Lancet Infectious Diseases|2024Cited by 48
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in childrenHamtandi Magloire Natama, Angela M. Minassian, Jo Salkeld et al.|The Lancet Infectious Diseases|2024Cited by 39
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled phase 2b trial in childrenHamtandi Magloire Natama, Angela M. Minassian, Jo Salkeld et al.|medRxiv|2024Cited by 1